amifostine anhydrous has been researched along with Rhabdomyolysis in 1 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Rhabdomyolysis: Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, JR | 1 |
| Krailo, M | 1 |
1 other study available for amifostine anhydrous and Rhabdomyolysis
| Article | Year |
|---|---|
The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
Topics: Amifostine; Child; Clinical Trials Data Monitoring Committees; Clinical Trials, Phase III as Topic; | 2011 |